$XCUR News

Exicure Q1 EPS $(0.29) Down From $0.49 YoY

Reported Earlier, Exicure And Adbiotech Partner To Evaluate Burixafor Combination Therapies In Multiple Indications Including Sickle Cell Disease And Acute Myeloid Leukemia

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure Reaches Settlement In Shareholder Derivative Lawsuit, Agrees To Governance Reforms And $675K Legal Fee Payment

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Q4 EPS $(0.22) Up From $(3.39) YoY.

On Feb 11, The Board Of Directors Of Exicure Appointed Jung Soo Kim As CEO And President; Appointed Gyuyeob Lee As Interim CFO; Andy Yoo Resigns As CEO And President; Seung Ik Baik Resigned As CFO

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure Announces Annals Of Hematology Publication Showing Burixafor Plus G-CSF Rapid Stem Cell Mobilization In Multiple Myeloma And Lymphoma Transplant Patients

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure To Present Burixafor Phase 2 Multiple Myeloma Stem Cell Mobilization Trial Data At 2026 Tandem Meetings Feb 4-7 In Salt Lake City

Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings

Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation achieved its primary endpoint.

Market-Moving News for December 9th

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Exicure Reports Phase 2 Results For Burixafor Combo In Multiple Myeloma; Achieves 90% Primary Endpoint In HPC Mobilization Ahead Of AHCT

Exicure, Inc. Reports Third Quarter 2025 Financial Results